找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: mTOR Inhibition for Cancer Therapy: Past, Present and Future; Monica Mita,Alain Mita,Eric K. Rowinsky Book 2016 Springer-Verlag France 201

[復(fù)制鏈接]
查看: 45884|回復(fù): 35
樓主
發(fā)表于 2025-3-21 19:18:56 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future
編輯Monica Mita,Alain Mita,Eric K. Rowinsky
視頻videohttp://file.papertrans.cn/643/642455/642455.mp4
概述First book on that topic.Input and perspectives by international leaders?.Preclinical and clinical data available on the subject have been integrated.A dedicated chapter on toxicity profile of mTOR in
圖書封面Titlebook: mTOR Inhibition for Cancer Therapy: Past, Present and Future;  Monica Mita,Alain Mita,Eric K. Rowinsky Book 2016 Springer-Verlag France 201
描述.This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.? .Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation. .
出版日期Book 2016
關(guān)鍵詞Akt; cancer; mTOR; rapamycin; Molecular
版次1
doihttps://doi.org/10.1007/978-2-8178-0492-7
isbn_softcover978-2-8178-0557-3
isbn_ebook978-2-8178-0492-7
copyrightSpringer-Verlag France 2016
The information of publication is updating

書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future影響因子(影響力)




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future影響因子(影響力)學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future網(wǎng)絡(luò)公開度




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future被引頻次




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future被引頻次學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future年度引用




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future年度引用學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future讀者反饋




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:49:01 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:30:30 | 只看該作者
地板
發(fā)表于 2025-3-22 08:32:38 | 只看該作者
https://doi.org/10.1007/978-2-8178-0492-7Akt; cancer; mTOR; rapamycin; Molecular
5#
發(fā)表于 2025-3-22 10:50:11 | 只看該作者
6#
發(fā)表于 2025-3-22 13:50:35 | 只看該作者
Monica Mita,Alain Mita,Eric K. RowinskyFirst book on that topic.Input and perspectives by international leaders?.Preclinical and clinical data available on the subject have been integrated.A dedicated chapter on toxicity profile of mTOR in
7#
發(fā)表于 2025-3-22 19:37:43 | 只看該作者
8#
發(fā)表于 2025-3-23 01:05:21 | 只看該作者
mTOR Inhibition for Cancer Therapy: Past, Present and Future978-2-8178-0492-7
9#
發(fā)表于 2025-3-23 01:51:49 | 只看該作者
Book 2016 already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation. .
10#
發(fā)表于 2025-3-23 06:28:40 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 13:01
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
富民县| 门头沟区| 普格县| 饶河县| 裕民县| 友谊县| 黑龙江省| 青阳县| 阳谷县| 广平县| 凤翔县| 台江县| 大足县| 绍兴市| 浦江县| 永修县| 印江| 隆德县| 松潘县| 永仁县| 嵊州市| 平乡县| 石门县| 本溪| 陆川县| 左云县| 綦江县| 察雅县| 东山县| 扶绥县| 县级市| 门源| 重庆市| 观塘区| 漳州市| 剑阁县| 龙里县| 安康市| 刚察县| 香格里拉县| 贵南县|